Atjaunināt sīkdatņu piekrišanu

Recent Advances in the Pathogenesis and Treatment of Kidney Diseases [Hardback]

Edited by , Series edited by
  • Formāts: Hardback, 148 pages, height x width: 255x190 mm, weight: 610 g, 22 fig., 12 in color, 17 tab.; 22 Illustrations
  • Sērija : Contributions to Nephrology 195
  • Izdošanas datums: 22-May-2018
  • Izdevniecība: S Karger AG
  • ISBN-10: 3318063495
  • ISBN-13: 9783318063493
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 185,40 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
  • Formāts: Hardback, 148 pages, height x width: 255x190 mm, weight: 610 g, 22 fig., 12 in color, 17 tab.; 22 Illustrations
  • Sērija : Contributions to Nephrology 195
  • Izdošanas datums: 22-May-2018
  • Izdevniecība: S Karger AG
  • ISBN-10: 3318063495
  • ISBN-13: 9783318063493
Citas grāmatas par šo tēmu:
This volume contains 14 papers by nephrologists and other medical specialists from Japan, who describe recent advances in the pathogenesis and treatment of kidney diseases. They address the role of caveolae in albumin passage through glomerular endothelial and epithelial cells; rituximab as a therapeutic option for steroid-sensitive minimal change nephrotic syndrome in adults; the clinical significance of evaluation of the largest renal corpuscle in kidney biopsy specimens; cystic kidney diseases; treatment strategies for lupus nephritis; the association between increases in normalized protein catabolic rate and increases in the creatinine generation rate in dialysis patients; renal anemia and iron metabolism; cell sheet engineering in the treatment of kidney diseases; the clinical impact of left ventricular diastolic dysfunction in chronic kidney disease; treatment of posttransplantation anemia; the role of frailty in outcomes of dialysis patients; the cost effectiveness of administering rituximab for nephrotic syndrome; the relationship between the use of beta-blockers on maintenance dialysis patients and ischemic cerebral and cardiovascular deaths; and the direct effects of immunomodulatory agents on podocytes in immune-mediated glomerular diseases. Annotation ©2018 Ringgold, Inc., Portland, OR (protoview.com)